[go: up one dir, main page]

HK1000093A1 - α-(4,5,6,7-四氫噻吩并[3,2-c]吡啶-5-基)(2-氯苯基)乙酸甲酯的右旋對映體及其製備以及藥物組合物 - Google Patents

α-(4,5,6,7-四氫噻吩并[3,2-c]吡啶-5-基)(2-氯苯基)乙酸甲酯的右旋對映體及其製備以及藥物組合物 Download PDF

Info

Publication number
HK1000093A1
HK1000093A1 HK97101520A HK97101520A HK1000093A1 HK 1000093 A1 HK1000093 A1 HK 1000093A1 HK 97101520 A HK97101520 A HK 97101520A HK 97101520 A HK97101520 A HK 97101520A HK 1000093 A1 HK1000093 A1 HK 1000093A1
Authority
HK
Hong Kong
Prior art keywords
salt
alpha
dextrogyre
enantiomer
acid
Prior art date
Application number
HK97101520A
Other languages
English (en)
French (fr)
Chinese (zh)
Other versions
HK1000093B (en
Inventor
Badorc Alain
Frehel Daniel
Original Assignee
赛诺菲 安万特
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26225786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1000093(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8702025A external-priority patent/FR2612929B1/fr
Application filed by 赛诺菲 安万特 filed Critical 赛诺菲 安万特
Publication of HK1000093B publication Critical patent/HK1000093B/xx
Publication of HK1000093A1 publication Critical patent/HK1000093A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Claims (4)

  1. Verfahren zur Herstellung des Hydrogensulfats des rechtsdrehenden Isomeren des α-(4,5,6,7-Tetrahydro-thieno[3,2-c]pyrid-5-yl)-(2-chlorphenyl)-essigsäuremethylesters, dadurch gekennzeichnet, daß man den racemischen α-(4,5,6,7-Tetrahydro-thieno[3,2-c]pyrid-5-yl)-(2-chlorphenyl)-essigsäuremethylester mit linksdrehender 10-Camphersulfonsäure in Aceton in das Salz überführt, aufeinander folgende Umkristallisationen des Salzes in Aceton bewirkt, bis man ein Produkt mit konstantem Drehwert erhält und dann das rechtsdrehende Isomere mit einer Base aus seinem Salz freisetzt und sein Salz mit Schwefelsäure bildet.
  2. Verfahren zur Herstellung einer pharmazeutischen Zubereitung, dadurch gekennzeichnet, daß man eine nach Anspruch 1 erhaltene Verbindung in eine pharmazeutisch annehmbare Form bringt.
HK97101520A 1987-02-17 1997-07-08 α-(4,5,6,7-四氫噻吩并[3,2-c]吡啶-5-基)(2-氯苯基)乙酸甲酯的右旋對映體及其製備以及藥物組合物 HK1000093A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8702025 1987-02-17
FR8702025A FR2612929B1 (fr) 1987-02-17 1987-02-17 Enantiomere dextrogyre de 1a-(tetrahydro- 4,5,6,7 thieno (3,2-c) pyridyl-5) (chloro-2 phenyl)-acetate de methyle, son procede de preparation et les compositions pharmaceutiques le renfermant
FR878716516A FR2623810B2 (fr) 1987-02-17 1987-11-27 Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR8716516 1987-11-27

Publications (2)

Publication Number Publication Date
HK1000093B HK1000093B (en) 1997-11-21
HK1000093A1 true HK1000093A1 (zh) 1997-11-21

Family

ID=26225786

Family Applications (1)

Application Number Title Priority Date Filing Date
HK97101520A HK1000093A1 (zh) 1987-02-17 1997-07-08 α-(4,5,6,7-四氫噻吩并[3,2-c]吡啶-5-基)(2-氯苯基)乙酸甲酯的右旋對映體及其製備以及藥物組合物

Country Status (36)

Country Link
US (1) US4847265A (de)
EP (1) EP0281459B1 (de)
JP (1) JPH0645622B2 (de)
KR (1) KR960003615B1 (de)
AR (1) AR243891A1 (de)
AT (1) ATE121745T1 (de)
AU (1) AU597784B2 (de)
CA (1) CA1336777C (de)
CS (1) CS274420B2 (de)
CY (1) CY2087B1 (de)
DE (2) DE19875053I2 (de)
DK (1) DK173636B1 (de)
ES (1) ES2071621T4 (de)
FI (1) FI87216C (de)
FR (1) FR2623810B2 (de)
HK (1) HK1000093A1 (de)
HR (1) HRP920923B1 (de)
HU (2) HU197909B (de)
IE (1) IE66922B1 (de)
IL (1) IL85294A (de)
LU (1) LU90324I2 (de)
LV (1) LV5804B4 (de)
MA (1) MA21184A1 (de)
MX (1) MX9203026A (de)
MY (1) MY103198A (de)
NL (1) NL990002I1 (de)
NO (2) NO165924C (de)
NZ (1) NZ223475A (de)
OA (1) OA08808A (de)
PH (1) PH25960A (de)
PL (1) PL156689B1 (de)
PT (1) PT86726B (de)
RO (1) RO99191B1 (de)
SI (1) SI8810231A8 (de)
TN (1) TNSN88012A1 (de)
YU (1) YU46748B (de)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065421A (en) * 1957-05-21 1962-11-20 John M Hart Radio-telephone communication system having means for automatic direct dispatch between mobile stations
US3009149A (en) * 1957-09-30 1961-11-14 Mcdonald Ramsey Automatic dial radio telephone system
US3105118A (en) * 1960-04-13 1963-09-24 Ericsson Telefon Ab L M Mobile radio stations interconnected with a wire telephone system
US4906756A (en) * 1988-05-10 1990-03-06 Syntex (U.S.A.) Inc. 2-(2-nitrovinyl)thiophene reduction and synthesis of thieno[3,2-c]pyridine derivatives
GB8824400D0 (en) * 1988-10-18 1988-11-23 Glaxo Group Ltd Chemical compounds
FR2664596B1 (fr) * 1990-07-10 1994-06-10 Sanofi Sa Procede de preparation d'un derive n-phenylacetique de tetrahydrothieno [3,2-c] pyridine et son intermediaire de synthese.
FR2672801B1 (fr) * 1991-02-14 1995-03-03 Sanofi Sa Utilisation de derives de tetrahydrothienopyridine comme inhibiteurs de l'angiogenese.
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
HU225504B1 (en) 1997-05-13 2007-01-29 Sanofi Aventis Novel halophenyl-(2-(2-thienyl)-ethylamino)-acetonitriles and process for producing them
HU225503B1 (en) * 1997-05-13 2007-01-29 Sanofi Aventis Novel 2-(2-halophenyl)-2-(2-(2-thienyl)-ethylamino)-acetamides and process for producing them
HU222283B1 (hu) * 1997-05-13 2003-05-28 Sanofi-Synthelabo Eljárás tieno[3,2-c]piridin-származékok előállítására
FR2769313B1 (fr) * 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
WO1999065500A1 (en) 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
FR2792836B3 (fr) 1999-04-30 2001-07-27 Sanofi Sa Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel
IN191030B (de) * 2001-01-24 2003-09-13 Cadila Healthcare Ltd
KR20060040758A (ko) * 2001-01-24 2006-05-10 카딜라 헬스케어 리미티드 티에노[3,2-ｃ]피리딘 유도체의 제조방법
US6495691B1 (en) 2001-07-06 2002-12-17 Brantford Chemicals Inc. Process for the preparation of tetrahydrothieno[3,2-c]pyridine derivatives
GB0125708D0 (en) * 2001-10-26 2001-12-19 Generics Uk Ltd Novel compounds and processes
CA2363053C (en) * 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
US6767913B2 (en) 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
CN1620293A (zh) * 2001-12-18 2005-05-25 特瓦制药工业有限公司 氯吡格雷硫酸氢盐的多晶型
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
HUP0200438A3 (en) * 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
CA2482858C (en) 2002-04-16 2010-11-30 Schering Corporation Tricyclic thrombin receptor antagonists
US6800759B2 (en) * 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
IL166593A0 (en) 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
CZ297472B6 (cs) * 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
US20040067995A1 (en) * 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
US6812363B2 (en) * 2002-10-15 2004-11-02 Usv Limited Racemization of optically active 2-substituted phenyl glycine esters
ITMI20022228A1 (it) * 2002-10-21 2004-04-22 Dinamite Dipharma S P A Sali di clopidogrel con acidi alchil-solforici.
AU2003285841A1 (en) * 2002-11-28 2004-06-18 Anpharm Przedsiebiorstwo Farmaceutyczne S.A. A process for the preparation of crystalline form 1 or clopidogrel hydrogen sulfate
EP1606231A1 (de) * 2003-02-03 2005-12-21 Nadkarni, Sunil Sadanand Verfahren zur herstellung von clopidogrel, seine salze und pharmazeutische zusammensetzungen
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
US7872019B2 (en) * 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
US6858734B2 (en) * 2003-04-23 2005-02-22 Rhodia Pharma Solutions Inc. Preparation of (S)-Clopidogrel and related compounds
US7732608B2 (en) * 2003-04-25 2010-06-08 Cadila Healthcare Limited Salts of clopidogrel and process for preparation
JP2007516166A (ja) * 2003-07-02 2007-06-21 エギシュ　ヂョヂセルヂャール　エルテー 血小板凝集阻害剤の無晶形の製法
WO2005003139A1 (en) * 2003-07-02 2005-01-13 EGIS Gyógyszergyár Rt. Process for the preparation of crystalline polymorph of a platelet aggregation inhibitor drug
DE10337773A1 (de) * 2003-08-13 2005-03-24 Krka Tovarna Zdravil, D.D. Kristallisation von festen Formen von Clopidogrel-Additionssalzen
GB0321256D0 (en) 2003-09-11 2003-10-08 Generics Uk Ltd Novel crystalline compounds
AU2008200919B2 (en) * 2003-09-11 2009-05-21 Generics (Uk) Limited Novel crystalline polymorphs of clopidogrel
EP1680430B1 (de) * 2003-11-03 2010-01-20 Cadila Healthcare Ltd. Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
CA2454015C (en) * 2003-12-23 2009-11-24 Brantford Chemicals Inc. A process for the preparation of tetrahydrothieno [3,2-c] pyridine derivatives
CA2457459A1 (en) * 2004-02-11 2005-08-11 Brantford Chemicals Inc. Resolution of racemates of methyl alpha-5-(4,5,6,7-tetrahydro(3,2-c)thienopyridyl)-(2-chlorophenyl) acetate
JP2007523203A (ja) * 2004-02-24 2007-08-16 ジークフリート・ジェネリクス・インターナショナル・アクチェンゲゼルシャフト クロピドグレルの薬理学的に許容できる塩
US7629465B2 (en) * 2004-03-05 2009-12-08 Ipca Laboratories Ltd. Industrial process for preparation of Clopidogrel hydrogen sulphate
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
JP4550884B2 (ja) * 2004-04-09 2010-09-22 ハンミ ファーム． シーオー．， エルティーディー． 結晶性クロピドグレルナフタレンスルホン酸塩又はその水和物、その製造方法及びそれを含む医薬組成物
KR100563455B1 (ko) * 2004-04-09 2006-03-23 한미약품 주식회사 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물
WO2005100364A1 (en) * 2004-04-19 2005-10-27 Krka, Tovarna Zdravil, D.D. Novo Mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
MXPA06012128A (es) * 2004-04-20 2007-01-31 Sanofi Aventis Sal de clopidogrel y formas polimorfas de la misma.
CN1997648A (zh) * 2004-04-20 2007-07-11 赛诺菲-安万特 (+)－(S)－α－(2－氯苯基)－6,7－二氢噻吩并[3,2－C]吡啶－5(4H)乙酸甲酯氢溴酸盐，即氯吡格雷氢溴酸盐的多晶型物
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
EP1750701A1 (de) * 2004-06-01 2007-02-14 IVAX Pharmaceuticals s.r.o. Amorphes clopidogrel-hydrochlorid und seine antithrombotische anwendung
EP1704152A2 (de) 2004-09-21 2006-09-27 Teva Pharmaceutical Industries Ltd Kristallines clopidogrelhydrobromid und verfahren zu dessen herstellung
US7446200B2 (en) * 2004-10-04 2008-11-04 Usv, Ltd. Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I
CZ295920B6 (cs) * 2004-10-18 2005-11-16 Zentiva, A. S Způsob výroby klopidogrelu
EP1674468A1 (de) * 2004-12-21 2006-06-28 Ratiopharm GmbH Polymorphe von Clopidogrel Hydrobromid
AU2005327776A1 (en) * 2005-02-15 2006-08-24 Usv Limited Rapid resolution process for clopidogrel base and a process for preparation of Clopidogrel bisulfate polymorph - Form I
EP1851231A2 (de) * 2005-02-24 2007-11-07 Teva Pharmaceutical Industries Ltd Zur pharmazeutischen formulierung geeignete clopidogrel-basis und deren herstellung
CZ299213B6 (cs) 2005-03-08 2008-05-21 Zentiva, A. S Zpusob racemizace R(-) izomeru methylesteru kyseliny (2-chlorfenyl)-6,7-dihydro-thieno[3,2-c]pyridin-5(4H)-octové
US7772398B2 (en) * 2005-03-11 2010-08-10 Dr. Reddy's Laboratories, Inc. Process for making crystalline form I of clopidogrel hydrogen sulphate
EP1888037A2 (de) * 2005-05-10 2008-02-20 Elan Pharma International Limited Clopidogrel-nanopartikelformulierungen
KR100678287B1 (ko) * 2005-06-23 2007-02-02 한미약품 주식회사 클로피도그렐의 제조방법 및 이에 사용되는 중간체
EP1902058A2 (de) * 2005-07-12 2008-03-26 RPG Life Sciences Limited Verfahren für die zubereitung von methyl-(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4h)-essigsäuremethylester oder salzen daraus mit höherer chiraler reinheit und produkte daraus
KR20070009851A (ko) * 2005-07-14 2007-01-19 씨제이 주식회사 클로피도그렐 황산수소염 함유 약학 조성물
WO2007052300A2 (en) * 2005-09-05 2007-05-10 Cadila Healthcare Limited Processes for the preparation of different forms of (s)-(+)-clopidogrel besylate
AU2006292946B2 (en) * 2005-09-21 2009-12-10 Chong Kun Dang Pharmaceutical Corp. Novel resinate complex of s-clopidogrel and production method thereof
KR100783286B1 (ko) * 2005-09-26 2007-12-06 주식회사종근당 클로피도그렐 우선성 광학이성체의 유리염기를 함유하는고형의 약제학적 조성물
DE102005060690B4 (de) * 2005-12-15 2008-09-25 Capsulution Nanoscience Ag Salze von Clopidogrel mit Polyanionen und ihre Verwendung zur Herstellung pharmazeutischer Formulierungen
KR101235117B1 (ko) * 2005-12-26 2013-02-20 에스케이케미칼주식회사 광학분리에 의한 (ｓ)-(＋)-클로피도그렐의 제조방법
KR20070094230A (ko) * 2006-03-17 2007-09-20 한미약품 주식회사 클로피도그렐 캄파술폰산염 또는 이의 결정다형을 함유하는약학 조성물
US20070225320A1 (en) * 2006-03-27 2007-09-27 Eswaraiah Sajja Process for preparing clopidogrel
MX349787B (es) 2006-04-04 2017-08-11 Kg Acquisition Llc Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
WO2007125544A2 (en) * 2006-04-27 2007-11-08 Ind-Swift Laboratories Limited Process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate
KR20080055860A (ko) * 2006-08-03 2008-06-19 테바 파마슈티컬 인더스트리즈 리미티드 클로피도그렐 바이설페이트의 제조 방법
US8247558B2 (en) * 2006-09-04 2012-08-21 Ranbaxy Laboratories Limited Process for the preparation of clopidogrel and its pharmaceutically acceptable salts
EP1900358A1 (de) 2006-09-16 2008-03-19 Cimex Pharma AG Clopidogrel enthaltende Arzneiformulierungen
SI22383A (sl) * 2006-09-22 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze klopidogrela in nove oblike njegovih farmacevtsko sprejemljivih soli
KR100978498B1 (ko) * 2006-10-17 2010-08-30 최중헌 클로피도그렐 황산수소염의 제조방법
WO2008060934A2 (en) * 2006-11-14 2008-05-22 Acusphere, Inc. Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
US20080194560A1 (en) * 2006-12-22 2008-08-14 Zhi Yun Wang Disintegration promoters in solid dose wet granulation formulations
EP1970054A3 (de) 2007-03-14 2009-06-03 Ranbaxy Laboratories Limited Clopidogrel-Tabletten
PL382055A1 (pl) * 2007-03-23 2008-09-29 Koźluk Tomasz Nobilus Ent Sposób wytwarzania formy krystalicznej 1 wodorosiarczanu klopidogrelu
EP1980563A1 (de) 2007-04-09 2008-10-15 BATTULA, Srinivasa Reddy Verfahren zur Herstellung von Methyl (+)-(S)-Alpha-(O-Chlorophenyl)-6,7-Dihydrothieno-[3,2-C]pyridine-5(4H) Acetat
EP2084164A2 (de) * 2007-04-18 2009-08-05 Teva Pharmaceutical Industries Ltd. Verbessertes verfahren zur herstellung von clopidogrel
CA2685331C (en) 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US20100297621A1 (en) * 2007-06-20 2010-11-25 University Of Utah Research Foundation Use of pre-mrna splicing in platelet cells for the diagnosis of disease
AU2008268625B2 (en) * 2007-06-22 2013-11-28 Bristol-Myers Squibb Holdings Ireland Unlimited Company Tableted compositions containing atazanavir
WO2009002826A2 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
CN101801348A (zh) * 2007-06-22 2010-08-11 百时美施贵宝公司 含有阿扎那韦的压片组合物
MX2009013461A (es) * 2007-06-22 2010-01-15 Bristol Myers Squibb Co Composiciones comprimidas que contienen atazanavir.
KR20090022616A (ko) * 2007-08-31 2009-03-04 한올제약주식회사 베실산클로피도그렐 함유 경구투여용 약제
CA2709262A1 (en) * 2007-12-14 2009-06-25 Generics [Uk] Limited New hplc method
WO2009080469A1 (en) * 2007-12-24 2009-07-02 Sandoz Ag Process for the preparation of clopidogrel bisulphate form i
EP2095815B1 (de) 2008-02-26 2011-10-26 Laboratorios Lesvi, S.L. Pharmazeutische Formulierungen mit Clopidogrel
RU2364394C1 (ru) * 2008-03-19 2009-08-20 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции клопидогрелем при l-name индуцированном дефиците оксида азота
MX2010010869A (es) 2008-04-01 2010-11-12 Astellas Pharma Inc Agente para prevenir y/o tratar enfermedades vasculares.
EP2107061A1 (de) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Herstellungsverfahren für optisch angereichertes Clopidogrel
US20090264460A1 (en) * 2008-04-21 2009-10-22 Mamta Mishra Clopidogrel pharmaceutical formulations
KR100990949B1 (ko) * 2008-06-09 2010-10-29 엔자이텍 주식회사 클로피도그렐 및 그의 유도체의 제조방법
US8299097B2 (en) * 2008-09-12 2012-10-30 The Brigham And Women's Hospital, Inc. Methods for treating inflammatory disorders
US20110190502A1 (en) * 2008-10-24 2011-08-04 Sandoz Ag Process for the preparation of s-clopidogrel
JP2012523438A (ja) 2009-04-10 2012-10-04 タフツ メディカル センター インコーポレイテッド メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化
CN101885730B (zh) * 2009-05-13 2012-07-04 连云港恒邦医药科技有限公司 抗血栓的化合物
KR101991367B1 (ko) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
CA2764172A1 (en) 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
KR20120050437A (ko) 2009-06-25 2012-05-18 테트라, 시아 신규한 아세틸살리실산 염들
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2011010318A1 (en) * 2009-07-23 2011-01-27 Praveen Laboratories Private Limited Process for the preparation of clopidogrel polymorphous form 1 using seed chrystals
WO2011042804A2 (en) 2009-10-08 2011-04-14 Jubliant Life Sciences Limited An improved process for the preparation of clopidogrel hydrogen sulfate form i
WO2011051976A2 (en) 2009-10-30 2011-05-05 Matrix Laboratories Ltd An improved process for the preparation of clopidogrel bisulfate form i
CN102863457B (zh) * 2010-02-02 2013-10-09 江苏威凯尔医药科技有限公司 光学活性2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途
CN101766573B (zh) 2010-02-05 2013-02-13 上海安必生制药技术有限公司 硫酸氢氯吡格雷固体制剂的制备工艺
WO2011101865A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Stable pharmaceutical compositions of clopidogrel for parenteral delivery
CN101787033B (zh) * 2010-03-16 2011-08-31 天津市中央药业有限公司 一种硫酸氢氯吡格雷有关物质c的合成方法
WO2011125069A1 (en) 2010-03-22 2011-10-13 Rpg Life Sciences Limited A process for preparation of crystalline form i of clopidogrel bisulfate
WO2011132201A1 (en) 2010-04-19 2011-10-27 Cadila Healthcare Limited A pharmaceutical composition comprising antiplatelet agents and an erythropoiesis stimulating agent
CN101863902B (zh) * 2010-06-29 2012-06-27 天津药物研究院 2-取代苯基-2-(4,5,6,7-四氢噻吩并[3,2-c]吡啶-5（4H）-基)乙酸(取代烷基醇)酯的制备方法和用途
WO2012007019A1 (en) 2010-07-13 2012-01-19 Pharmathen S.A. Process for the preparation of clopidogrel and salts thereof
WO2012123958A1 (en) 2011-02-14 2012-09-20 Cadila Healthcare Limited Highly pure salts of clopidogrel free of genotoxic impurities
CN102199160B (zh) * 2011-03-22 2016-06-22 浙江华海药业股份有限公司 一种制备ⅰ型硫酸氢氯吡格雷的方法
BR112013033464A2 (pt) 2011-06-27 2017-01-24 Ipca Lab Ltd composto, acetato, composição farmacêutica, combinação farmacêutica, método e método melhorado
CN104114163A (zh) 2011-12-09 2014-10-22 沃克哈特有限公司 治疗心血管疾病的方法
CN103665042B (zh) * 2012-09-21 2016-03-16 北京普禄德医药科技有限公司 光学活性的2-羟基四氢噻吩并吡啶衍生物及其制备方法和用途
WO2014118802A1 (en) 2013-01-31 2014-08-07 Pharmazell Gmbh An improved process for the preparation of clopidogrel bisulfate form-i
CN104761567A (zh) * 2014-01-02 2015-07-08 上海医药工业研究院 一种硫酸氢氯吡格雷、其中间体及制备方法
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
KR101710922B1 (ko) 2015-06-03 2017-02-28 경동제약 주식회사 클로피도그렐 황산염 결정형 i형의 제조방법
CN107698620A (zh) 2015-06-23 2018-02-16 江苏天士力帝益药业有限公司 一种氘代噻吩并哌啶衍生物、制备方法及其应用
EP3646865A4 (de) 2017-06-30 2021-03-17 Kowa Company, Ltd. Medizin
CN110627808B (zh) * 2018-06-21 2022-04-01 江苏同禾药业有限公司 一种硫酸氢氯吡格雷拆分母液的回收处理工艺
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
WO2023012479A1 (en) 2021-08-03 2023-02-09 Liqmeds Worldwide Limited An oral pharmaceutical solution of clopidogrel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
DE3621413A1 (de) * 1986-06-26 1988-01-07 Boehringer Ingelheim Kg Verwendung carbocyclisch und heterocyclisch annelierter dihydropyridine als cardioprotektive mittel sowie neue heterocyclisch und carbocyclisch anellierte dihydropyridine, verfahren zu deren herstellung und zwischenstufen fuer deren herstellung
DE3736664A1 (de) * 1987-10-29 1989-05-11 Boehringer Ingelheim Kg Tetrahydro-furo- und -thieno(2,3-c)pyridine, ihre verwendung als arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
ATE121745T1 (de) 1995-05-15
MX9203026A (es) 1992-07-01
AR243891A1 (es) 1993-09-30
DK80088D0 (da) 1988-02-16
ES2071621T3 (es) 1995-07-01
NO1999022I1 (no) 1999-10-11
HRP920923B1 (en) 2001-12-31
FI880720L (fi) 1988-08-18
DE19875053I2 (de) 2001-05-23
US4847265A (en) 1989-07-11
CS274420B2 (en) 1991-04-11
NO165924B (no) 1991-01-21
HRP920923A2 (hr) 1994-04-30
CY2087B1 (en) 2002-04-05
TNSN88012A1 (fr) 1990-07-10
FI87216B (fi) 1992-08-31
DE3853643T2 (de) 1995-11-30
LV5804B4 (lv) 1997-08-20
DK173636B1 (da) 2001-05-14
LU90324I2 (fr) 1999-01-27
CA1336777C (en) 1995-08-22
MY103198A (en) 1993-05-29
FI87216C (fi) 1992-12-10
PL270677A1 (en) 1988-12-08
JPH0645622B2 (ja) 1994-06-15
NZ223475A (en) 1989-05-29
EP0281459A1 (de) 1988-09-07
NO165924C (no) 1991-05-02
IL85294A (en) 1991-12-15
KR960003615B1 (ko) 1996-03-20
YU46748B (sh) 1994-04-05
JPS63203684A (ja) 1988-08-23
FR2623810B2 (fr) 1992-01-24
IE66922B1 (en) 1996-02-07
EP0281459B1 (de) 1995-04-26
FI880720A0 (fi) 1988-02-16
NO880666L (no) 1988-08-18
NL990002I1 (nl) 1999-03-01
IL85294A0 (en) 1988-07-31
PL156689B1 (en) 1992-04-30
AU1129288A (en) 1988-08-18
MA21184A1 (fr) 1988-10-01
DE3853643D1 (de) 1995-06-01
FR2623810A2 (fr) 1989-06-02
HUT47291A (en) 1989-02-28
YU23188A (en) 1989-08-31
RO99191B1 (ro) 1990-07-30
ES2071621T4 (es) 2011-12-29
PT86726B (pt) 1992-05-29
OA08808A (fr) 1989-03-31
KR880009969A (ko) 1988-10-06
SI8810231A8 (en) 1996-08-31
HU197909B (en) 1989-06-28
DK80088A (da) 1988-08-18
LV5804A4 (lv) 1997-02-20
AU597784B2 (en) 1990-06-07
PT86726A (pt) 1988-03-01
PH25960A (en) 1992-01-13
HU210538A9 (en) 1995-04-28
NO880666D0 (no) 1988-02-16
IE880273L (en) 1988-08-17
CS96588A2 (en) 1990-09-12

Similar Documents

Publication Publication Date Title
HK1000093A1 (zh) α-(4,5,6,7-四氫噻吩并[3,2-c]吡啶-5-基)(2-氯苯基)乙酸甲酯的右旋對映體及其製備以及藥物組合物
HK1000093B (en) Dextrorotatory enantiomer of alpha-(4, 5, 6, 7-tetrahydrothienod3, 2-capyrid-5-yl)(2-chlorophenyl)methyl acetate, process for its preparation and pharmaceutical c.
IE862805L (en) Benzimidazole derivatives
IE58393B1 (en) (R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
SU1468422A3 (ru) Способ получени производных гризеоловой кислоты
HU195653B (en) Process for preparing dihydro-pyridyl-benzothiophene and thienopyridine derivatives
US4500534A (en) Thieno-pyridinone derivatives, process for its preparation, and anti-blood-platelet and anti-thrombotic applications thereof
AU632949B2 (en) 3-{(5-methyl-2-furanyl)methyl}-n-(4-piperidinyl)-3 h-imidazo {4,5-b}-pyridin-2-amine 2-hydroxy-1, 2,3-propanetricarboxylate
EP0035868A1 (de) Bicyclische Verbindungen, ihre Herstellung und Verwendung
US4668674A (en) (+)-6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)-acetyl]-11H-dibenzo[b,][1,4]diazepin-11-one, the isolation thereof and its use as a pharmaceutical material
US4031223A (en) Trifluoromethylthio derivatives of cyproheptadine
US4435420A (en) Anti-inflammatory agents and antiasthmatic agents
EP2460803B1 (de) Verfahren zur herstellung eines thiabenzoazulenpropionsäurederivats
EP0160451B1 (de) Isomere von Derivaten der Dihydropyridin-3,5-dicarboxylsäureester, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
CA1234121A (en) Hexahydro-3,5-dioxo-1h-pyrrolizine-2-carboxylic acid and derivatives as cognition activators
US4612324A (en) Imidazole derivatives for treating joint diseases and Wilson's disease
US4621087A (en) Anti-anoxic furo- or pyrrolo-pyridine compounds and pharmaceutical compositions containing them
US4500708A (en) Benzothiazine derivatives
US5444077A (en) Ameliorant of cerebral circulation and optical isomer of NB-818, processes for its use
FR2555580A1 (fr) Nouveaux composes azabicycliques, procede pour les preparer et medicaments les contenant
SU1438611A3 (ru) Способ получени производных 1,5-бензоксатиепина или его кислотно-аддитивных солей
KR100791687B1 (ko) 결정성 클로피도그렐 설포살리실산 염을 포함하는 제제
WO2001064647A1 (en) Isoquinoline derivatives as pde4 inhibitors
KR100742134B1 (ko) 결정성Ｓ-(+)-메틸-2-(2-클로로페닐)-2-(6,7-디히드로티에노[3,2-ｃ]피리딘-5(4Ｈ)-일)아세테이트·캄실레이트를 포함하는약학적 조성물
FI88039C (fi) Foerfarande foer framstaellning av 2,3-dihydro-1-(8-metyl-1,2,4-triatsolo/4,3-b/pyridazin-6-yl)-4(1h)-pyridinon

Legal Events

Date Code Title Description
PF Patent in force
CHPA Change of a particular in the register (except of change of ownership)
PE Patent expired

Effective date: 20080215